Janux Therapeutics Inc ( (JANX) ) has issued an announcement.
Janux Therapeutics announced promising interim results for its JANX007 clinical program targeting prostate cancer, showing high PSA response rates and robust anti-tumor activity in patients. The Phase 1a trial demonstrated significant efficacy and a well-tolerated safety profile, with notable PSA declines in treated patients. These findings support ongoing development and expansion into further trials, highlighting JANX007’s potential as a differentiated therapy for advanced prostate cancer. The company plans to continue updates as they advance their clinical strategy.
Learn more about JANX stock on TipRanks’ Stock Analysis page.